Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04451109 · ClinicalTrials.gov registry record
Dilapan-S®: A Multicenter US E-registry
A clinical trial of Gestational Diabetes and Fetal Growth Retardation, sponsored by Medicem Technology s.r.o..
- Active
- Registry status
- 1,200
- Enrollment target
- 1
- Study location
NCT04451109: Active study of Gestational Diabetes and Fetal Growth Retardation, sponsored by Medicem Technology s.r.o..
NCT04451109 is a study of Gestational Diabetes and Fetal Growth Retardation that is active but no longer recruiting, run by Medicem Technology s.r.o.. The registered enrollment target is 1,200 participants, above the 293-participant average among 41 other Gestational Diabetes trials with a reported enrollment target (310% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04451109, a study of Gestational Diabetes and Fetal Growth Retardation, is active but no longer recruiting, sponsored by Medicem Technology s.r.o..
- ACTIVE NOT RECRUITING
- Registry status
- 1,200 participants
- Enrollment target
- 1
- Study location
Study Summary
Objective of this registry is to collect a representative set of real world data on the use of Dilapan-S® for pre-induction cervical ripening in daily clinical practice. Upon completion of the registry, relevant collected data will be analyzed and published.
Conditions Studied
Interventions
- DEVICE Dilapan-S
Study Locations (1)
Texas
- The University of Texas Medical Branch - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2025-06-30 |
What the registry record for NCT04451109 still lists
NCT04451109 is an observational study that tracks outcomes without assigning an intervention. Its 1,200 participants enrollment target places it among the larger protocols in the corpus, above the 293-participant average among 41 other Gestational Diabetes trials with a reported enrollment target (310% higher).
The record links to 6 conditions, with Gestational Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Dilapan-S is the first listed.
NCT04451109 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04451109 about?
NCT04451109 is a clinical study titled "Dilapan-S®: A Multicenter US E-registry". Objective of this registry is to collect a representative set of real world data on the use of Dilapan-S® for pre-induction cervical ripening in daily clinical practice. Upon completion of the registry, relevant collected data will be analyzed and published.
What is the current status of trial NCT04451109?
This trial is currently active not recruiting. The enrollment target is 1,200 participants. The study started on 2020-12-01. Estimated completion is 2025-06-30.
What conditions does trial NCT04451109 study?
This clinical trial studies the following conditions: Gestational Diabetes, Fetal Growth Retardation, Premature Rupture of Membrane, Oligohydramnios, Post Term Pregnancy.
What interventions are being tested in trial NCT04451109?
The interventions under investigation include: Dilapan-S (DEVICE).
Who is sponsoring clinical trial NCT04451109?
This trial is sponsored by Medicem Technology s.r.o., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04451109 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gestational Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04451109's enrollment target sits among peer trials
1,200 4th of 41 higher than 38 of 41 other Gestational Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gestational Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nutrition Optimization and Community Upliftment for Postpartum Recovery
RECRUITING · NA
-
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)
RECRUITING · NA
-
Delivering HOPE (Helping Women Optimize Prenatal Equity)
RECRUITING · NA
-
iGlucose® Remote Patient Monitoring Device as an Adjunct to Routine Glucose Meter Devices for Glycemic Management and Control in Gestational Diabetes
RECRUITING · NA
-
Evaluating the Efficacy of GPT-based Nutrition and Diabetic Counseling in Gestational Diabetes Management: A Randomized Controlled Trial (AIM-GDM)
RECRUITING · NA
-
Growth Hormone Resistance of Beta-cells
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
- NCT01944332 · 1,200 participants · NA
Gamete Treatment to Correct Fertilization Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI